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A genome-wide association study yields
ﬁve novel thyroid cancer risk loci
Julius Gudmundsson1, Gudmar Thorleifsson1, Jon K. Sigurdsson1, Lilja Stefansdottir1, Jon G. Jonasson2,3,4,
Sigurjon A. Gudjonsson1, Daniel F. Gudbjartsson1, Gisli Masson1, Hrefna Johannsdottir1, Gisli H. Halldorsson1,
Simon N. Stacey1, Hannes Helgason1,5, Patrick Sulem1, Leigha Senter6, Huiling He7, Sandya Liyanarachchi7,
Matthew D. Ringel8, Esperanza Aguillo9, Angeles Panadero10, Enrique Prats11, Almudena Garcia-Castan˜o12,
Ana De Juan12, Fernando Rivera12, Li Xu13, Lambertus A. Kiemeney14, Gudmundur I. Eyjolfsson15,
Olof Sigurdardottir16, Isleifur Olafsson2, Hoskuldur Kristvinsson2, Romana T. Netea-Maier17,
Thorvaldur Jonsson2,3, Jose I. Mayordomo18, Theo S. Plantinga19, Hannes Hjartarson2, Jon Hrafnkelsson2,
Erich M. Sturgis13, Unnur Thorsteinsdottir1,3, Thorunn Rafnar1, Albert de la Chapelle7 & Kari Stefansson1,3
The great majority of thyroid cancers are of the non-medullary type. Here we report ﬁndings
from a genome-wide association study of non-medullary thyroid cancer, including in total
3,001 patients and 287,550 controls from ﬁve study groups of European descent. Our results
yield ﬁve novel loci (all with Pcombinedo3 108): 1q42.2 (rs12129938 in PCNXL2), 3q26.2
(rs6793295 a missense mutation in LRCC34 near TERC), 5q22.1 (rs73227498 between NREP
and EPB41L4A), 10q24.33 (rs7902587 near OBFC1), and two independently associated var-
iants at 15q22.33 (rs2289261 and rs56062135; both in SMAD3). We also conﬁrm recently
published association results from a Chinese study of a variant on 5p15.33 (rs2736100 near
the TERT gene) and present a stronger association result for a moderately correlated variant
(rs10069690; OR¼ 1.20, P¼ 3.2 10 7) based on our study of individuals of European
ancestry. In combination, these results raise several opportunities for future studies of the
pathogenesis of thyroid cancer.
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T
hyroid cancer is the most common malignancy of the
endocrine system and its incidence in industrialized
countries has been rising over the past few decades.
At present the incidence rate of thyroid cancer is 7.4 and 22.0
per 100,000 in the United States (US) for males and females of
European ancestry, respectively1. In Iceland, the incidence rate is
4.1 and 10.7 for males and females, respectively2.
Thyroid tumours are classiﬁed into four main histology groups:
papillary (PTC), follicular (FTC), medullary (MTC) and undif-
ferentiated or anaplastic thyroid carcinomas. The majority of all
thyroid tumours are non-medullary; either PTC (80-85%) or FTC
(10-15%)3,4.
Thyroid cancer has been shown to have one of the strongest
genetic component of all cancers, and the effect has been shown
to extend beyond the nuclear family5–7. In an attempt to discover
sequence variants conferring risk of thyroid cancer we previously
performed two thyroid cancer genome-wide association studies
(GWASs) in which we discovered, and published8,9, ﬁve risk
variants, located on 2q35, 9q22.33, 8p12 and 14q13.3.
These variants have since been widely replicated by other study
groups10–14.
The purpose of our current study was to continue our search
for thyroid cancer risk variants by building on our two previous
thyroid cancer GWASs. Hence, we have expanded our study
group as well as the number of markers analysed. This expansion
provided us with both additional marker density and statistical
power, resulting in the discovery of ﬁve new thyroid cancer risk
loci, located at: 1q42.2, 3q26.2, 5q22.1 10q24.33 and 15q22.33.
These results highlight several new potential focus points for
future thyroid cancer research studies.
Results
Imputation and GWAS data. To search for additional thyroid
cancer risk loci, we reanalysed our Icelandic GWAS data set after
having expanded it close to seven-fold in terms of total number of
participants included in the study and approximately doubling
the number of variants analysed from our previously reported
study9. The increase in number of variants is based on whole
genome sequencing (WGS) of 15,220 Icelanders to an average
depth of 34.5 (see Methods). The Icelandic non-medullary
thyroid cancer GWAS results are based on 1,003 patients
and 278,991 controls (see Supplementary Table 1). Apart from
previously reported8,9 variants or their correlates, located on:
2q35, 8p12, 9q22.33 and 14q13.3, no variants met our genome-
wide signiﬁcance criteria (Supplementary Table 2). The threshold
for genome-wide signiﬁcance in the present study was corrected
for multiple testing using a weighted Bonferroni procedure based
on functional impact of classes of variants15 (GWAS signiﬁcance
thresholds range between 2.6 10 7 and 7.9 10 10 depending
on functional annotations; see Methods).
We then conducted a meta-analysis including the Icelandic
results and four additional case-control groups of European
descent, with populations from Columbus, Ohio and Houston,
Texas, in the United States (US), the Netherlands and Spain. The
number of study subjects in the Columbus study group has been
increased by over four-fold from the previously reported9, and
the Houston study group has not been included in any of the
previously published GWASs of thyroid cancer. All these study
subjects were whole-genome analysed for the ﬁrst time in the
present study by genotyping them using the Illumina Quad array
chip genotyping platform. For the Spanish and the two US-study
groups we performed genome-wide imputation using the 1000
Genomes Phase 3 Project data. For the Dutch study group, the
genome-wide imputation was done using The Genome of
the Netherlands16 (GoNL) whole-genome sequencing data set
(see Methods). In total, the non-Icelandic data set consists of
1,998 patients and 8,559 controls. Per-allele odds ratios and P
values for all variants in each of the ﬁve study group GWAS
analyses were obtained using a logistic regression model.
There was little evidence of systematic over dispersion of
the test statistic (lGC¼ 1.021–1.079; Supplementary Fig. 1). A
ﬁxed-effects meta-analysis was conducted for 7.1 million variants
(with imputation info scoreZ0.90 in all study groups) in a total
of 3,001 thyroid cancer patients and 287,550 controls.
Association with thyroid cancer. The strongest associations were
with previously reported8,9 thyroid cancer risk variants or with
variants in strong linkage disequilibrium (LD) with them, located
on: 2q35, 8p12, 9q22.33 and 14q13.3 (Fig. 1, Table 1 and
Supplementary Table 2). Only at the 2q35 locus was the variant
reported in the present study (rs11693806) signiﬁcantly stronger
than the previously reported rs966423 (results for rs11693806[C]
conditioned on rs966423: OR¼ 1.31; P¼ 9.5 10 8;
whereas results for rs966423[C] conditioned on rs11693806 are:
OR¼ 1.03; P¼ 0.61, see Supplementary Table 3). We also
discovered ﬁve new regions, located on: 1q42.2, 3q26.2, 5q22.1,
10q24.33, 15q22.33, containing variants that are genome-wide
signiﬁcantly associated with thyroid cancer (Table 2 and Supple-
mentary Fig. 2). The 15q22.33 locus contains two variants that
associate with thyroid cancer independent of each other (see
Table 3).
Unlike the thyroid cancer risk variants previously reported8,9,
none of the variants at these new risk loci is signiﬁcantly
associated (after correcting for multiple testing: Po0.01) with
serum levels of thyroid-related hormones (that is, thyroid
stimulating hormone (TSH), free-triiodothyronine (fT3) or free-
thyroxine (fT4); see Supplementary Fig. 3 and Supplementary
Table 4). Also, none of the newly discovered variants had a
signiﬁcant association with gender or age at diagnosis. However,
the number of samples of the follicular subtype is too few to
allow a meaningful comparison of the effect size for different
histological subtypes of thyroid cancer.
Results for other previously reported risk variants. During the
preparation of this manuscript, Ge et al.17 reported results from
an association study of thyroid cancer in Chinese, analysing
haplotype tagging variants located in the TERT-CLPTM1L region
on 5p15.33; a region reported to contain several variants
associated with risk of cancer in several organs. They found a
signiﬁcant association between rs2736100[C] and thyroid cancer
in the Chinese. Results in the present study conﬁrm this ﬁnding
in populations of European ancestry (rs2736100[C]: OR¼ 1.11;
P¼ 7.3 10 4, see Supplementary Table 3). However, in our
study the strongest association results in this region were for
rs10069690[T] (OR¼ 1.20; P¼ 3.2 10 7, see Table 2). Based
on the 1000 Genome Project data set, the correlation between
rs10069690 and rs2736100 is moderate in both individuals of
European ancestry (r2¼ 0.27) and Asians (r2¼ 0.26). When we
condition the two variants on each other, only results for
rs10069690[T] remain signiﬁcant (P¼ 1.3 10 4 conditioned
on rs2736100; compared to P¼ 0.11 for rs2736100[C]
conditioned on rs10069690, see Supplementary Table 3). Hence,
it is likely that the association signals of these two variants reﬂect
the same signal although rs10069690 seems to confer a slight
reﬁnement of it when moving from the Chinese to the European
ancestry study groups.
For other previously reported18–21 GWAS-identiﬁed thyroid
cancer risk variants, we nominally replicate results19 for
rs13184587 located on 5q14.1 (OR¼ 1.08, P¼ 0.040; see Supple-
mentary Data set 1).
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Table 1 | Results for the strongest variants in the current study for the ﬁve previously reported thyroid cancer risk loci.
Locus Marker*
(EA/OA)
Position
(bp)
Annotation EAF Allelic OR
(95% CI)
P value Pairwise correlation with previously
reported SNP (r2)
2q35 rs11693806
(C/G)
Phet¼0.0069;
I2¼ 71.7
217,427,435 Non-coding transcript
exon variant
0.319 1.43
(1.33, 1.54)
1.5 10 24 0.47 with rs966423
8p12 rs2466076
(G/T)
Phet¼0.41;
I2¼0
32,575,278 Intron variant 0.484 1.32
(1.23, 1.41)
1.5 10 17 0.94 with rs2439302
9q22.33 rs1588635
(A/C)
Phet¼0.48;
I2¼0
97,775,520 Intergenic variant 0.396 1.69
(1.59, 1.82)
2.0 10 58 0.99 with rs965513
14q13.3 rs368187 (G/C)
Phet¼0.089;
I2¼ 50.5
36,063,370 Non-coding transcript
exon variant
0.581 1.39
(1.30, 1.47)
5.1 10 23 0.70 with rs944289
14q13.3 rs116909374
(T/C)
Phet¼0.85;
I2¼0
36,269,155 Intergenic variant 0.034 1.81
(1.57, 2.08)
1.1 10 16 same as current SNP
Shown is: the chromosomal locus, the risk markers and the effect allele (EA), the other allele (OA), the position of the marker in base pairs (bp) with reference to Build 38, the functional annotation
(Annotation) according to Variant Effect Predictor (VEP) (ref. 60), the average unweighted effect allele frequency (EAF) in controls, the allelic odds ratio (OR) for the effect allele with 95% conﬁdence
interval (CI), the P value and the correlation coefﬁcient (r2) between the marker reported in the present study and the marker previously reported8,9 for each of the ﬁve loci. Association testing was
performed using the likelihood ratio statistic and results from different study groups were combined using a Mantel-Haenszel model (see Methods).
Note that marker rs116909374 on 14q13.3 is still the strongest association signal at that locus in the current meta-analysis. Shown is the P value for the heterogeneity (Phet) between the different study
groups and the heterogeneity statistic (I2) representing the fraction of variability due to heterogeneity between study groups.
*For all markers but rs116909374, was the imputation information scoreZ0.97 and the association results shown are imputed results from the meta-analysis of the Icelandic, US (Columbus, Ohio and
Houston, Texas), Dutch and Spanish study groups. For rs116909374 the combined results are made up of imputed data from Iceland (with imputation information score¼ 1.0) and directly generated
genotypes for the other four study groups.
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Figure 1 | A Manhattan plot of the combined thyroid cancer GWAS results. The Manhattan plot shows 7.1 million variants with high imputation
information score (infoZ0.90) from the thyroid cancer meta-analysis of GWAS data from 3,001 patients and 287,550 controls from ﬁve study groups of
European descent coming from Iceland, the Netherlands, Spain and the USA. Shown are negative log10-transformed P values over 22 autosomes. Previously
published risk loci are in black and risk loci reported in current study are in red.
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Bioinformatics- and eQTL analyses of the novel risk variants.
We next performed a bioinformatics- and eQTL (expression
quantitative trait locus) analyses, searching for inﬂuences of these
newly discovered variants on biologically functional elements or
gene expression in normal thyroid tissue. Several variants yielded
interesting results and had robust association with gene expres-
sion (see Supplementary Data set 2). The most interesting ﬁnd-
ings based on these analyses are discussed below.
At 1q42.2 the lead SNP rs12129938[A] (OR¼ 1.32; P¼ 4.0
 10 11) lies within an enhancer in the ﬁrst intron of PCNXL2.
Little is known about the function of PCNXL2 but it is highly
conserved and mainly expressed in the brain according to the
GTEx Portal (accessed 12 June 2016: http://www.gtexportal.org/
home/).
The second most signiﬁcant variant, rs7902587[T] (OR¼ 1.41;
P¼ 5.4 10 11), is located at 10q24.33, approximately16Kb
upstream of OBFC1. According to the HaploReg browser (acce-
ssed 1 June 2016: http://www.broadinstitute.org/mammals/hap-
loreg/haploreg.php), rs7902587 is located in an enhancer region
in fetal brain tissue. Several other variants, highly correlated
(r2Z0.75) with rs7902587, have several hits within both
promoters and enhancers in many different tissue types,
including the thyroid. OBFC1 is a subunit of an alpha accessory
factor (AAF) that stimulates the activity of DNA polymerase-
alpha-primase, the enzyme that initiates DNA replication22.
OBFC1 also appears to function in a telomere-associated protein
complex (with C17ORF68 and TEN1 (ref. 23)). rs7902587 also
correlates (r2¼ 0.74) with variants reported24,25 to associate with
longer telomeres as well as with a strongly correlated variant
(r2¼ 0.94) conferring risk of melanoma26.
rs73227498[A] (OR¼ 1.37; P¼ 3.0 10 10) at 5q22.1 is
located in an intergenic region approximately 394Kb upstream
of NREP and 12Kb downstream of EPB41L4A. According to
GTEx, EPB41L4A has the second highest expression in thyroid of
all tissues analysed (see Supplementary Fig. 4). However, the
association of the thyroid cancer risk allele (rs73227498[A]) with
expression of EPB41L4A (P¼ 3.0 10 6) becomes non-signiﬁ-
cant when conditioned on the most signiﬁcant cis-eQTL signal
(rs821749) for EPB41L4A (P¼ 0.29 for association of rs73227498
with expression of EPB41L4A when conditioned on rs821749).
rs821749 is not genome-wide signiﬁcantly associated with thyroid
cancer (P¼ 0.0015) in our study. Members of the EPB41L4A gene
superfamily are thought to regulate the interaction between the
cytoskeleton and plasma membrane. This locus also contains
other variants strongly correlated (r2Z0.75) with rs73227498 that
are located within regulator elements detected in several different
Table 2 | Association results for ﬁve new genome-wide signiﬁcant loci and the variant replicating the 5p15.33 locus.
Locus Lead marker (EA/OA) Position (bp) Annotation/Nearby gene(s) EAF Study group Allelic OR (95% CI) P value
1q42.2 rs12129938 (A/G) 233,276,815 Intron variant PCNXL2 0.783 Iceland 1.37 (1.20, 1.54) 9.1 10 7
Phet¼0.73; I2¼0 0.810 Columbus, USA 1.23 (1.10, 1.41) 5.9 104
0.808 Houston, USA 1.28 (0.96, 1.70) 0.091
0.786 The Netherlands 1.28 (0.88, 1.85) 0.19
0.789 Spain 1.56 (1.06, 2.27) 0.024
0.795 All combined 1.32 (1.20, 1.43) 4.0 10 11
3q26.2 rs6793295 (T/C) 169,800,667 Missense variant TERC, LRRC34 0.780 Iceland 1.30 (1.16, 1.47) 1.9 10 5
Phet¼0.68; I2¼0 0.755 Columbus, USA 1.19 (1.06, 1.33) 0.0018
0.764 Houston, USA 1.28 (0.98, 1.67) 0.068
0.734 The Netherlands 1.27 (0.90, 1.79) 0.18
0.760 Spain 1.02 (0.70, 1.47) 0.93
0.759 All combined 1.23 (1.15, 1.33) 2.7 10 8
5p15.33 rs10069690 (T/C) 1,279,675 Intron variant TERT 0.259 Iceland 1.25 (1.12, 1.40) 4.8 10 5
Phet¼0.49; I2¼0 0.277 Columbus, USA 1.12 (1.00, 1.25) 0.043
0.306 Houston, USA 1.21 (0.94, 1.57) 0.14
0.247 The Netherlands 1.38 (0.97, 1.96) 0.074
0.284 Spain 1.40 (0.99, 1.98) 0.059
0.275 All combined 1.20 (1.12, 1.29) 3.2 10 7
5q22.1 rs73227498 (A/T) 112,150,207 Intergenic variant NREP, EPB41L4A 0.855 Iceland 1.35 (1.16, 1.56) 8.1 10 5
Phet¼0.30; I2¼ 17.7 0.891 Columbus, USA 1.39 (1.20, 1.61) 1.4 10 5
0.898 Houston, USA 1.67 (1.19, 2.33) 0.0030
0.849 The Netherlands 0.92 (0.60, 1.41) 0.69
0.869 Spain 1.28 (0.81, 2.04) 0.29
0.872 All combined 1.37 (1.23, 1.49) 3.0 10 10
10q24.33 rs7902587 (T/C) 103,934,543 Intergenic variant OBFC1 0.095 Iceland 1.40 (1.21, 1.63) 1.0 10 5
Phet¼0.42; I2¼0 0.120 Columbus, USA 1.32 (1.12, 1.55) 8.2 104
0.138 Houston, USA 1.52 (1.06, 2.19) 0.024
0.096 The Netherlands 2.23 (1.34, 3.73) 0.0022
0.094 Spain 1.44 (0.83, 2.48) 0.19
0.109 All combined 1.41 (1.27, 1.56) 5.4 10 11
15q22.33 rs2289261 (C/G) 67,165,147 Intron variant SMAD3 0.669 Iceland 1.17 (1.05, 1.30) 0.0037
Phet¼0.24; I2¼ 26.7 0.700 Columbus, USA 1.33 (1.19, 1.47) 1.9 10 7
0.703 Houston, USA 1.30 (1.02, 1.66) 0.037
0.666 The Netherlands 1.14 (0.82, 1.58) 0.43
0.678 Spain 0.95 (0.68, 1.33) 0.77
0.683 All combined 1.23 (1.15, 1.32) 3.1 109
Position is according to Build 38 of the reference genome. Shown is the effect allele (EA), the other allele (OA), the effect allele frequency in controls (EAF), the allelic odds ratio (OR) for the effect allele
with upper and lower 95% conﬁdence intervals (CI) and the P value for association testing between variants and disease which was performed using the likelihood ratio statistic. Results from different
study groups were combined using a Mantel-Haenszel model (see Methods). Annotation is according to Variant Effect Predictor (VEP) (ref. 60). Shown are also the P value for the heterogeneity (Phet)
between the different study groups and the heterogeneity statistic (I2) representing the fraction of variability due to heterogeneity between study groups. All markers listed in table had imputation
information scoreZ0.95.
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tissues, including from the thyroid (see Supplementary Data
set 2).
The 15q22.33 locus contains two independent association
signals: rs2289261[C] with OR¼ 1.23; P¼ 3.1 10 9, and
rs56062135[T] with OR¼ 1.24; P¼ 4.9 10 9 (see Table 3).
The two variants are located intronic in SMAD3 that is an
important transcriptional mediator of transforming growth
factor-b (TGF-b) signalling. SMAD3 is most highly expressed
in the thyroid of all tissues analysed according to GTEx (see
Supplementary Fig. 5), and the thyroid cancer risk alleles of
the two variants associate with increased expression of SMAD3
in normal thyroid tissue, (rs56062135[T] has b¼ 0.46
s.d., P¼ 4.8 10 14, and rs2289261[C] has b¼ 0.29 s.d., P¼ 1.6
 10 6). According to GTEx, the association between
rs56062135 and SMAD3 expression in thyroid tissue is the
strongest cis-eQTL association signal reported for this gene
(þ / 1Mb around transcript start site). A conditional analysis
of the expression data, adjusting the two variants for each other,
demonstrates that both remain signiﬁcant, although results for
rs56062135 retain more of the signiﬁcance (rs56062135[T],
adjusted for rs2289261, had b¼ 0.40 s.d., P¼ 4.2 10 10,
and rs2289261[C], adjusted for rs56062135, had b¼ 0.14 s.d.,
P¼ 0.021).
At 3q26.2, the lead variant, rs6793295[T] (OR¼ 1.23; P¼ 2.7
 10 8), is a missense mutation (p.Ser249Gly) in LRRC34 and
has (either itself or through a highly correlated variant) been
previously reported to associate with several diseases and other
traits, speciﬁcally: pulmonary ﬁbrosis27, bladder cancer28,
multiple myeloma29,30 and telomere length25,31,32. Little is
known about the function of LRRC34 but its role has been
suggested to be in ribosome biogenesis in pluripotent stem cells33.
No signiﬁcant association with expression of any gene is
reported for rs6793295[T] in thyroid tissue, according to GTEx,
but the strongest eQTL associations are with decreased expression
of LRRC34 in transformed ﬁbroblasts, tibial tissue and
subcutaneous adipose tissue (b¼  0.35 s.d.,  0.39 s.d.,
and  0.28 s.d., respectively; P¼ 1.5 10 8, 6.7 10 8 and
7.9 10 8, respectively). In addition to the lead variant,
numerous variants, highly correlated (r2Z0.75) with rs6793295,
are associated with thyroid cancer at this locus (see Supple-
mentary Data set 2). Among them is another missense variant,
rs10936600 (p. Leu286Ile), in LRRC34 and a splice-region variant
rs9822885 in ACTRT3, a neighbouring gene. Another interesting
gene located at this locus is TERC, which is the RNA component
of the telomerase, involved in maintenance of telomeres. Variants,
located at this region and strongly correlated (r2Z0.95) with the
thyroid cancer risk variant, have been reported31,32 to associate
with telomere length and, the allele conferring risk of thyroid
cancer is correlated with the allele associated with longer
telomeres.
As discussed above, rs10069690[T] (OR¼ 1.20; P¼ 3.2
 10 7) is the strongest variant at 5p15.33 in our analysis. It
is located in the fourth intron of the TERT gene and has
previously been reported to confer risk of estrogen receptor
negative breast- and ovarian cancer34. The authors of that
study concluded that the cancer risk was not due to a telomere
length association signal also reported by them for mode-
rately correlated variants within this region (rs2736108 and
rs7705526 have an r2 with rs10069690 of 0.04 and 0.34,
respectively). Interestingly, the thyroid cancer risk allele of the
variant (rs2736100[C]) reported in the Chinese study has also
been found to associate with longer telomeres25 but that variant
is only moderately correlated with the one reported in
this region in our study (r2¼ 0.27 between rs10069690 and
rs2736100 in EUR) and therefore it is unclear if telomere length
plays a role in conferring risk of thyroid cancer at this locus.
Another study35 found the thyroid cancer risk allele of
rs10069690[T] to be protective of prostate cancer and
associated with increased expression of TERT in benign
prostate tissue. According to GTEx, the expression level of
TERT in normal thyroid tissue is too low to draw meani-
ngful conclusion. Several other variants at this locus have
been associated with numerous diseases, both benign and
malignant according to the GWAS Catalog (The NHGRI-EBI
Catalog of published GWASs (accessed on 21 June 2016):
https://www.ebi.ac.uk/gwas/home).
Table 3 | Results from the conditional analysis of the 15q22.33 locus showing two independent association signals.
Marker (EA/OA) Position (bp) EAF Study group Unadjusted results for rs2289261_C Results for rs2289261_C adjusted on
rs56062135
Allelic OR (95% CI) P value Allelic OR (95% CI) P value
rs2289261 (C/G) 67,165,147 0.669 Iceland 1.17 (1.05, 1.30) 0.0037 1.08 (0.97, 1.21) 0.17
0.700 Columbus, USA 1.33 (1.19, 1.47) 1.9 10 7 1.27 (1.13, 1.43) 5.3 10 5
0.703 Houston, USA 1.30 (1.02, 1.66) 0.037 0.87 (0.39, 1.92) 0.73
0.666 The Netherlands 1.14 (0.82, 1.58) 0.43 1.09 (0.77, 1.55) 0.63
0.678 Spain 0.95 (0.68, 1.33) 0.77 0.78 (0.53, 1.14) 0.20
0.683 All combined 1.23 (1.15, 1.32) 3.1 10 9 1.14 (1.06, 1.23) 6.6 104
Phet¼0.24; I2¼ 26.7 Phet¼0.072; I2¼ 53.5
Unadjusted results for
rs56062135_T
Results for rs56062135_T adjusted on
rs2289261
Allelic OR (95% CI) P value Allelic OR (95% CI) P value
rs56062135 (T/C) 67,163,292 0.231 Iceland 1.23 (1.10, 1.37) 2.2 104 1.19 (1.05, 1.34) 0.0049
0.279 Columbus, USA 1.24 (1.11, 1.39) 2.2 104 1.11 (0.98, 1.25) 0.093
0.271 Houston, USA 1.25 (0.95, 1.64) 0.11 0.62 (0.23, 1.66) 0.34
0.239 The Netherlands 1.17 (0.82, 1.67) 0.39 1.12 (0.77, 1.62) 0.55
0.243 Spain 1.50 (1.04, 2.16) 0.029 1.66 (1.12, 2.47) 0.012
0.253 All combined 1.24 (1.16, 1.34) 4.9 10 9 1.16 (1.07, 1.26) 3.1 104
Phet¼0.89; I2¼0 Phet¼0.25; I2¼ 26.3
Shown are association results from the meta-analysis before and after conditional analysis, the marker and the corresponding effect allele (EA) and the other allele (OA), the genomic position in base
pairs (bp) with reference to Build 38, the allelic odd ratio (OR) of the effect allele with 95% conﬁdence intervals (CI) and the P value generated using the likelihood ratio statistic. Results from different
study groups were combined using a Mantel-Haenszel model (see Methods) The correlation (r2) in Iceland between rs2289261 and rs56062135 is 0.15. Shown is the P value for the heterogeneity (Phet)
between the different study groups and the heterogeneity statistic (I2) representing the fraction of variability due to heterogeneity between study groups. Both markers in table had imputation
information scoreZ0.99.
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Discussion
In summary, our meta-analysis has yielded ﬁve new thyroid
cancer susceptibility loci. In addition, we conﬁrm a risk locus
recently reported17 in a study of Chinese thyroid cancer patients.
Similarly, as with the bulk of previously reported thyroid cancer
risk variants, the majority of these newly discovered variants are
located either intronic or intergenic. Recently, the importance of
this group of ‘noncoding’ variants has been coming clearer, as
demonstrated for two of the previously discovered thyroid cancer
risk variants, located intergenic at 9q22 and 14q13, and shown to
affect the expression and events downstream of long non-coding
RNA genes36–38. Interestingly, three of the variants reported here
are located in regions reported to associate with telomere length
and for two of them (rs6793295 on 3q26.2 and rs7902587 on
10q24.33) the allele associated with longer telomeres is correlated
with the allele conferring risk of thyroid cancer. For the third
variant (rs10069690 on 5p15.33) the correlation is weaker
(r2¼ 0.27 between rs10069690 and rs2736100) even though the
direction of the association with thyroid cancer and telomere
length is the same as for the other two variants. However,
it remains to be determined what biological features account
for involvement of these variants in the pathogenesis of non-
medullary thyroid cancer.
Methods
Study populations. All Icelandic participants in this study are of European
ancestry. Icelanders diagnosed with thyroid cancer were identiﬁed based on a
nationwide list from the Icelandic Cancer Registry (ICR) (http://www.krabba-
meinsskra.is/indexen.jsp?icd=C73) that contains all Icelandic thyroid cancer
patients diagnosed from 1 January 1955, to 31 December 2015. Thereof, 1,108 were
non-medullary thyroid cancers. Out of the total list, genotypic information was
available from 1,003 (71% are females) individual for the current study and their
mean age at diagnosis is 53 years. The 278,991 Icelandic controls (49% females)
used in this study consist of individuals belonging to different genetic research
projects at deCODE. The controls had a mean age of 57 years. The controls were
absent from the nationwide list of thyroid cancer patients according to the ICR.
The study was approved by the Data Protection Commission of Iceland and the
National Bioethics Committee of Iceland. Written informed consent was obtained
from all subjects. Personal identiﬁers associated with medical information and
blood samples were encrypted with a third-party encryption system as previously
described39.
The Dutch study population consists of 85 non-medullary thyroid cancer cases
(70% are females) and 4,956 cancer-free individuals (55% females). The cases were
recruited from the Department of Endocrinology, Radboud University Medical
Center (Radboudumc), Nijmegen, The Netherlands from November 2009 to June
2010. All patients were of self-reported European descent. Demographic and
clinical characteristics were obtained from the patient’s medical records. The
average age at diagnosis of the patients was 40 years and average age of the controls
was 55 years. The DNA for both the Dutch cases and controls was isolated from
whole blood using standard methods. The controls were recruited within a project
entitled ‘Nijmegen Biomedical Study’ (NBS). For a detailed description of this
study, see Galesloot et al.40 The study was approved by the Ethical Committee and
the Institutional Review Board of the Radboudumc, Nijmegen, The Netherlands
and all study subjects gave written informed consent.
All subjects recruited in Columbus, USA, and included in the current study
were of self-reported European descent and provided written informed consent.
The 1,580 patients have a mean age of diagnosis of 43 years (74% are females) and
were histologically conﬁrmed papillary or follicular thyroid carcinoma (PTC)
patients (including traditional PTC and follicular variant PTC). The 1,628 controls
have a mean age of 45 years (74% are females) and are individuals without
clinically diagnosed thyroid cancer from the central Ohio area. Genomic DNA was
extracted from blood. The study was approved by the Institutional Review Board of
the Ohio State University.
The study population recruited in Houston, USA, consisted of 250 papillary
thyroid cancer (PTC) patients (69% are females) and 363 cancer-free controls (56%
are females). The diagnosis of PTC was assigned by histologic review of the surgical
or biopsy specimen, and the controls were recruited from among visitors to the
institution. All subjects were of self-reported European descent. The mean age of
diagnosis of PTC patients was 45 years and the mean age of controls at recruitment
was 53 years. Genomic DNA was extracted from buffy coat cells isolated from
peripheral blood. The study was approved by the MD Anderson Cancer Center
Institutional Review Board and each subject provided written informed consent.
The Spanish study population consisted of 83 non-medullary thyroid cancer
cases. The cases were recruited from the Oncology Department of Zaragoza
Hospital in Zaragoza, Spain, from October 2006 to June 2007. All patients were of
self-reported European descent. Clinical information including age at diagnosis,
grade and stage was obtained from medical records. The average age at diagnosis
for the patients was 49 years (71% are females). The 1,612 Spanish control
individuals (51% are females) had a mean age of 47 and were approached at
the University Hospital in Zaragoza, Spain, and were not known to have thyroid
cancer. The DNA for both the Spanish cases and controls was isolated from whole
blood using standard methods. Study protocols were approved by the Institutional
Review Board of Zaragoza University Hospital. All subjects gave written informed
consent.
Thyroid-related hormone measurements. TSH, fT4 and fT3 levels were mea-
sured in blood samples of Icelanders seeking medical care between the years 1997
and 2015 at the Landspitali University Hospital, the Clinical Laboratory in Mjodd,
Reykjavik, Iceland, and Akureyri Hospital, Akureyri, Iceland. The QTL association
results are based on measurements for the following number of Icelanders:
TSH¼ 188,057 individuals; fT3¼ 51,047 individuals; fT4¼ 120,879 individuals.
The measurements were normalized to a standard normal distribution using
quantile-quantile normalization and then adjusted for centre, gender, year of birth
and age at measurement. For individuals for which more than one measurement
was available we used the average of the adjusted normalized values. A generalized
form of linear regression that accounts for the relatedness between individuals was
used to test for the association of quantitative traits (that is, TSH, fT3 and fT4),
with sequence variants.
Genotyping and statistical methods. The Icelandic thyroid cancer GWAS data
set used in the current study is based on WGS, chip genotyping and long-range
phasing of Icelandic population samples41. In brief, we whole genome sequenced
15,220 Icelanders using Illumina technology (Illumina, San Diego, CA, USA) to an
average depth of at least 34 , resulting in the identiﬁcation of some 94 million
variants. Using imputation assisted by long-range haplotype phasing42,43 and after
removing variants with imputation information content below 0.8 as well as with
an imputed minor allele frequency below 0.01%, we successfully inferred the
genotypes of 32,463,443 variants in 434,571 Icelanders, of whom 151,677 had been
genotyped using the Illumina chip genotyping platform. The remaining 282,894
Icelanders are ﬁrst- and second-degree relatives of the chip-typed individuals and
are imputed by aid of genealogic information. Of the patients used in this study 639
(64%) were chip genotyped and the remaining 364 were imputed by aid of
genealogical information. Comparable numbers for the controls used are 126,251
(45%) chip genotyped and the remaining 152,739 were imputed by aid of
genealogical information. In the meta-analysis only variants with imputation info
scoreZ0.9 were included.
The Dutch, Spanish and US study samples were genotyped using Omni-1
Quad-bead chips (Illumina, San Diego, CA, USA). For each sample set, variants
were excluded if they (i) hado94% yield, (ii) hado1% MAF, (iii) failed Hardy-
Weinberg test (Po1 10 6) or (iv) showed signiﬁcant (Po1 10 6) difference
between genotype batches. Samples witho94% yield were excluded. The resulting
genotypes were phased using SHAPEIT (v2.790) (ref. 44), and used to impute un-
genotyped variants using IMPUTE2 (v2.3.2) (ref. 45). All but the Dutch samples
were imputed using the 1000 Genomes Phase 3 reference data (October 2014
release) that includes phased genotypes for about 80 million variants and for 2,504
individuals of various ethnicities46. The Dutch study samples were imputed using
the GoNL (ref. 16) data set generated by whole-genome sequencing of 249 Dutch
trios (498 unrelated parents and 249 children).
Single track assay SNP genotyping. For validation purposes we directly geno-
typed the variants reported in Table 2 of the main text for a sub-set of 2,754 cases
and controls form all ﬁve case-control groups of the present study. The correlation
(r2) between imputed and directly genotyped was above 0.92 for all markers. Due
to low imputation information score (ranging between 0.72 and 0.78) for
s116909374 on 14q13.3 in the non-Icelandic study groups, this variant was directly
genotyped in all available samples and the results combined with the Icelandic
imputation results (which had imputation score¼ 1.0) and presented in Table 1
and in Supplementary Table 2, The direct genotyping was carried out by deCODE
Genetics in Reykjavik, Iceland, applying the Centaurus47 (Nanogen) platform.
Population structure. To study the population structure and the ancestry of
samples in the Dutch, Spanish and US cohorts we used the ADMIXTURE (v 1.2)
(ref. 48) and EIGENSOFT (v 6.0.1) (ref. 49) software. Samples were excluded if
they were identiﬁed as ethnic outliers in the respective cohort, and to adjust for
remaining population substructure ten principle components were included as
covariates in the subsequent association analysis. Likewise, for the Icelandic cohort
population, substructure was adjusted for by including county of origin as a
covariate in the analysis.
Association testing. Logistic regression was used to test for association between
variants and disease, assuming a multiplicative model, treating disease status as the
response and expected genotype counts from imputation as covariates. For the
Icelandic cohort this was done using software developed at deCODE genetics41, but
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the Dutch, Spanish and US cohorts were analysed using the SNPTEST (v.2.5)
software50. Testing was performed using the likelihood ratio statistic. For the
Icelandic study group patients and controls are matched on gender and age at
diagnosis or age at inclusion but for the other study groups we did not adjust for
these factors. Variants in the 1000 Genomes and GoNL imputation data sets were
mapped to NCBI Build38 positions and matched to the variants in the Icelandic
data set based on allele variation. Results from the different study groups were
combined using a Mantel-Haenszel model51 in which the groups were allowed to
have different population frequencies for alleles and genotypes but were assumed to
have a common OR. Heterogeneity was tested by comparing the null hypothesis of
the effect being the same in all populations to the alternative hypothesis of each
population having a different effect using a likelihood ratio test. I2 lies between 0
and 100% and describes the proportion of total variation in study estimates that is
due to heterogeneity.
Association signiﬁcance thresholds. The threshold for genome-wide signiﬁcant
association in the current study was corrected for multiple testing using a class-
speciﬁc Bonferroni procedure based on functional impact of classes of variants15.
This yielded signiﬁcance thresholds of: (i) 2.6 10 7 for 8,474 high-impact
variants (comprised of: stop-gained, frameshift, splice acceptor or donor),
(ii) 5.1 10 8 for 149,983 moderate-impact variants (comprised of: missense,
splice-region variants and in-frame INDELs), (iii) 4.6 10 9 for 2,283,889 low
impact variants (comprised of: synonymous variants 30 and 50 UTR variants),
(iv) 2.3 10 9 for 3,913,058 intergenic and deep intronic variants overlapping
DNase hypersensitivity sites and (v) 7.9 10 10 for 26,108,039 other variants
(intergenic and deep intronic).
Genomic control adjustment. To account for inﬂation in test statistics
due to cryptic relatedness and stratiﬁcation within the case and control
sample sets, we applied the method of LD score regression52. With a
set of 1.1million variants we regressed the w2 statistics from our GWAS
scan against LD score and used the intercept as a correction factor. The LD
scores were downloaded from an LD score database (accessed 23 June2015:
ftp://atguftp.mgh.harvard.edu/brendan/1k_eur_r2_hm3snps_se_weights.RDS).
The estimated correction factor was 1.079 for the Icelandic samples, mostly due
to relatedness of the individuals; all P values in the Icelandic GWAS study were
adjusted for this inﬂation. For the other study groups, the genomic adjustment
factors were modest, in all cases below 1.043, and this was not adjusted for. For
the combined meta-analysis, the correction factor was estimated to be 1.031.
Bioinformatics analysis. To inspect if the thyroid cancer risk variants might have
regulatory effects or be located within regions with predicted biological features we
performed an analysis selecting the lead variant at each of the newly discovered risk
loci as well as all variants strongly correlated (r2Z0.75) with the lead variant. For
this set of variants, we searched for overlaps with known regulatory regions as
follows: ﬁrst we used ENSEMBL to determine whether the variant had been
assigned a regulatory region ENSR number. Then we examined the ENCODE data
and looked for any evidence of ChIP-Seq transcription factor binding and DNaseI
hypersensitivity sites53,54. We also looked for enhancer and promoter chromatin
segmentation states using the 25-state HMM from the Roadmap consortium55.
Then we looked for correlations between DNaseI hypersensitive sites and local
gene expression using results described by Shefﬁeld et al.56. Finally, we searched for
eQTL associations between variants and genes using publicly available data57,58,
and gene targets of distal enhancers using looping chromatin59.
Expression analysis. Gene expression and genotype data for 278 thyroid tissues
from the GTEx Release phs000424.v6. p1 from 5.10.2015 (GTEx Analysis V6) were
downloaded from the GTEx consortium57 via dbGAP. Linear regression analysis
for expression of SMAD3 and genotypes of rs73227498 and rs821749 on 5q22.1 as
well as for rs2289261 and rs56062135 on 15q22.33 was performed using quantile
normalized expression values and the following covariates from GTEx: 3
genotyping principal components, gender, genotyping platform (Illumina’s OMNI
5M or 2.5M array) and 35 PEER factors.
Data availability. The Icelandic population WGS data have been deposited at the
European Variant Archive under accession code PRJEB8636. The authors declare
that the data supporting the ﬁndings of this study are available within the article, its
Supplementary Information ﬁles and on request.
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